Pfizer chief Bourla raises 'likely' need for annual COVID shots, teeing up vaccine sales for years to come

Pfizer was first to market in the U.S. with its BioNTech-partnered COVID-19 vaccine, and by and large, it's avoided the safety and supply concerns plaguing some of its pandemic peers. Now, to hear CEO Albert Bourla tell it, it's increasingly likely the 2021 revenue boon will continue for years to come. Patients will "likely" need a third dose of Pfizer and BioNTech's COVID-19 vaccine as the shot's protection wanes, CEO Albert Bourla said in a recent interview with CVS Health Live.
Read more...

;